Up­dat­ed: FDA ap­proves Mi­rati's KRAS drug in non-small cell lung can­cer

FDA grant­ed ac­cel­er­at­ed ap­proval to Mi­rati’s KRAS drug ada­gra­sib, which will be mar­ket­ed as Kraza­ti. The green light comes two days ahead of the ex­pect­ed de­ci­sion and ce­ments the biotech as the sec­ond in the KRAS field be­hind leader Am­gen, mak­er of the May 2021-ap­proved Lumakras.

The nod is for sec­ond-line treat­ment for adult pa­tients with KRAS G12C-mu­tat­ed lo­cal­ly ad­vanced or metasta­t­ic non-small cell lung can­cer (NSCLC).

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN